Posts

Sangamo puts substantially all assets up for sale in bankruptcy, lines up Lilly and Astellas as buyers

on

Regeneron doubles down on CytomX despite other pharma exits, expanding pact to up to ~$4 billion potential value

on

Astellas five‑year plan targets record sales and deep cost cuts through 2030

on

Astellas Submits Supplemental New Drug Application in Japan for PADCEV (Enfortumab Vedotin) + Keytruda (Pembrolizumab) for Muscle-Invasive Bladder Cancer

on

Astellas Highlights Positive Early Data from Stem Cell-Derived RPE Therapy for Geographic Atrophy

on

Astellas Pharma Top Management Personnel Changes (October 2025)

on

Astellas Pharma to Close Seattle Universal Cells Office with 50 Employee Layoffs

on

Astellas Announces Top Management Personnel Change: Nick Eshkenazi to Depart as CDTO

on

Astellas Ends Partnership with CytomX Despite Positive Phase 1 Data for Probody Platform

on

Astellas and Vir Biotechnology Announce $1.7B Collaboration for VIR-5500 Prostate Cancer Drug, Including $240M Cash Upfront

on

Astellas Pharma Revises Financial Forecasts for FY2025

on

Astellas Pharma Revises Financial Forecasts for FY2025

on

Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends

on

Bayer's Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas' Hot Flash Drug

on

Pfizer, Astellas' Xtandi Combo Extends Survival in Early Prostate Cancer

on

Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences

on

FDA Approves Extended Dosing for Astellas' Izervay, Intensifying Competition in Geographic Atrophy Treatment

on

FDA Approves Extended Dosing for Astellas' Izervay in Geographic Atrophy Treatment

on